12 results on '"Themistoklis Karmiris"'
Search Results
2. Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
- Author
-
Theodoros P. Vassilakopoulos, Fotios Panitsas, Zois Mellios, John Apostolidis, Alexia Piperidou, Michalis D Michael, Ronit Gurion, Meltem Akay, Eleftheria Hatzimichael, Stamatis J. Karakatsanis, Maria Dimou, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Chara Giatra, Nikolaos Kanellias, Ayman Sayyed, Tamar Tadmor, Leylagul Kaynar, Miri Zektser, Argiris Symeonidis, SC Atalar, Evgenia Verrou, Odit Gutwein, Chezi Ganzel, Giorgos Karianakis, Jonathan Isenberg, Gabriela Gainaru, Theodora Triantafyllou, Efimia Vrakidou, Maria Palassopoulou, Mehmet Ozgur, Semra Paydas, Panagiotis Tsirigotis, Maria Tsirogianni, Tulin Tuglular, Chrysovalantou Chatzidimitriou, Maria Kotsopoulou, Evangelos Terpos, Panagiotis Zikos, Argyro Koumarianou, Christos Poziopoulos, Dimitrios Boutsis, Anat Gafter-Gvili, Themistoklis Karmiris, Maria K. Angelopoulou, Maria Bakiri Papaioannou, Gerassimos Pangalis, Panayiotis Panayiotidis, Burhan Ferhanoglu, Netanel A. Horowitz, and Sotirios Papageorgiou
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
3. MANTLE CELL LYMPHOMA, A SINGLE CENTER EXPERIENCE
- Author
-
M Bouzani, G Tounta, Stavros Gigantes, V Babali, Dimitra Rontogianni, I Tsonis, I Darmani, A Roumelioti, P Kosmas, K Kaouranis, D Ikonopoulou, M Dellatola, E Andreou, M. Bakiri, K. Sakellariou, F Karaolidou, D Gardeli, A Loutsidi, E.-K Dimitraki, Z Mellios, K Souravla, G Kanellis, N El-Gkotmi, C Giatra, Tatiana Tzenou, Ioannis Baltadakis, D Karakasis, L Ligdi, and Themistoklis Karmiris
- Subjects
Cancer Research ,Oncology ,Cancer research ,medicine ,Mantle cell lymphoma ,Hematology ,General Medicine ,Single Center ,medicine.disease ,Geology - Published
- 2021
4. RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES
- Author
-
A. Koumarianou, Argyris Symeonidis, Leylagül Kaynar, Saime Paydas, Nikolaos Kanellias, Chezi Ganzel, G. Isenberg, Themistoklis Karmiris, Olga Meltem Akay, E. Megalakaki, M. Ozgur, George Karianakis, Eleftheria Hatzimichael, Miri Zektser, M. Palassopoulou, Eirini Katodritou, O. Gutwein, Chrysovalantou Chatzidimitriou, Stamatios Karakatsanis, Maria Tsirogianni, Tulin Firatli Tuglular, Maria K. Angelopoulou, Z. Mellios, Anat Gafter-Gvili, Effimia Vrakidou, T.P. Vassilakopoulos, Gabriella Gainaru, Christina Kalpadakis, A. C. Atalar, Ronit Gurion, Marina P. Siakantaris, Panayiotis Tsirigotis, Panagiotis Zikos, Sotirios G. Papageorgiou, Burhan Ferhanoglu, Theoni Leonidopoulou, Tamar Tadmor, Netanel A. Horowitz, and A. Piperidou
- Subjects
Cancer Research ,medicine.medical_specialty ,Oncology ,business.industry ,medicine ,Rituximab ,Primary Mediastinal Large B-Cell Lymphoma ,Hematology ,General Medicine ,EPOCH (chemotherapy) ,Radiology ,business ,medicine.drug - Published
- 2021
5. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database
- Author
-
Fotios Panitsas, Christina Kalpadakis, Vassilios Xanthopoulos, Gerassimos Tsourouflis, Kostas Konstantopoulos, Eleftheria Hatzimichael, Stamatis Karakatsanis, Maria Dimou, Eleni Variamis, Maria Papaioannou, Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis, Sotirios G. Papageorgiou, Ioannis Kotsianidis, Meletios A. Dimopoulos, Alexia Piperidou, Ioannis Batsis, Ioannis Vassilopoulos, Evdoxia Hadjiharissi, Themistoklis Karmiris, Theoni Leonidopoulou, Maria K. Angelopoulou, Alkistis-Kyra Panteliadou, Eirini Katodritou, Panayiotis Panayiotidis, Dimitrios Boutsis, Maria Kotsopoulou, Niki Stavroyianni, Evgenia Verigou, and Michail Michail
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Databases, Factual ,MEDLINE ,Mediastinal Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Primary Mediastinal Large B-Cell Lymphoma ,Survival rate ,Hematology ,business.industry ,Follow up studies ,medicine.disease ,Prognosis ,Hodgkin Disease ,Lymphoma ,Survival Rate ,Hodgkin lymphoma ,Female ,Lymphoma, Large B-Cell, Diffuse ,business ,Follow-Up Studies - Published
- 2020
6. Viral Reactivation after T Cell Replete Haploidentical Stem Cell Transplantation: Increased Incidence in Association with Immune Reconstitution
- Author
-
Maria Bouzani, Zois Mellios, Maria Katsareli, Tatiana Tzenou, Dimitris Karakasis, Dimitra Oikonomopoulou, Chara Giatra, Ioannis Baltadakis, Dimitra Gardeli, Stavros Gigantes, Ioannis Tsonis, Themistoklis Karmiris, Maria-Eleni Karatza, and Eirini Grispou
- Subjects
Transplantation ,medicine.medical_specialty ,Cellular immunity ,Myeloid ,Cyclophosphamide ,business.industry ,Hematology ,medicine.disease ,medicine.disease_cause ,Gastroenterology ,BK virus ,Letermovir ,medicine.anatomical_structure ,Internal medicine ,medicine ,Rituximab ,business ,Hemorrhagic cystitis ,medicine.drug - Abstract
Feasibility of haploidentical stem cell transplantation (haploSCT) is enhanced by use of post-transplant cyclophosphamide (PTCY). Despite preservation of non-alloreactive T cells, delayed reconstitution of cellular immunity and viral reactivation may compromise the outcome of T cell replete haploSCT. The study included 47 patients, aged 19-70 (median, 53) years, who underwent haploSCT with PTCY for myeloid (n=35) or lymphoid (n=12) malignancies. Myeloablative conditioning was mainly utilized (n=36). Graft source was peripheral blood (n=29) or bone marrow (n=18). Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human herpesvirus-6 (HHV-6) reactivation was monitored by real-time quantitative PCR (RQ-PCR) in plasma and/or leukocytes weekly for at least 6 months. BK virus (BKV) reactivation was assessed by RQ-PCR in urine and/or blood in cases with hemorrhagic cystitis (HC). Preemptive therapy was the principal modality for CMV infection in all but 1 patient who received letermovir prophylaxis. Reconstitution of cellular immunity was assessed by flow cytometry. With a median follow-up of 30 months, cumulative incidences (CIN) of relapse and non-relapse mortality were 13.4% (95% CI, 5.4-25.1%) and 31.4% (95% CI, 18.3-45.4%) at 2 years, respectively. Disease-free and overall survival were 55.2% (95% CI, 42.3-72.1%) and 61.8% (95% CI, 48.9-78.1%) at 2 years, respectively. CIN of CMV reactivation (>100 copies/ml) plateaued at 75.6% (95% CI, 60.1-85.7%) at 3 months. CMV infection developed in 34/45 patients at risk. Recurrent CMV infection occurred in 17/34 with median 1.5 (range, 1-6) episodes per patient. Median duration of anti-CMV therapy was 27 (range, 14-199) days. CMV disease was documented in 2 patients. CIN of EBV reactivation (>1,000 copies/ml) was 47.1% (95% CI, 34.2-63.9%) at 1 year, and preemptive therapy with rituximab was required in 2 patients. HHV-6 reactivation (>1,000 copies/ml) was observed in 6 patients (CIN, 10.6% at 6 months; 95% CI, 3.8-21.4%). CIN of BKV-related HC reached 27.7% (95% CI, 15.7-40.9%) at 3 months. Cystoscopy was required in 5/13 and nephrostomy in 1/13 patients. Reconstitution of T cell immunity was considerably delayed, with median CD4+ cell counts of 83/uL (range, 7-337), 216/uL (range, 80-509), and 236/uL (range, 97-586) at 3, 6 and 12 months, respectively. Recurrent CMV infection was associated with the recovery of CD4+ cells at 3 months (Figure, median CD4+ count of 191/uL versus 62/uL in patients with 1 or ³2 episodes of CMV reactivation, respectively; p=0.009). Haplo-SCT with PTCY is associated with substantial rates of viral reactivation resulting in the need for prolonged antiviral therapy and considerable morbidity as well. Strategies to prevent viral infection are strongly warranted. The timing and duration of such interventions (like letermovir or adoptive immunotherapy) may be guided by the tempo of immune reconstitution.
- Published
- 2020
7. Increased Incidence of Viral Reactivation after T Cell Replete Haploidentical Stem Cell Transplantation in Association with Delayed Immune Reconstitution
- Author
-
Tatiana Tzenou, Maria Bouzani, Ioannis Tsonis, Chara Giatra, Ioannis Baltadakis, Stavros Gigantes, Eirini Grispou, Maria Katsareli, Kimon Fountoulis, Dimitra Oikonomopoulou, Georgia Tounta, Themistoklis Karmiris, Maria-Eleni Karatza, Dimitrios Karakasis, and Zois Mellios
- Subjects
Foscarnet ,Cellular immunity ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Immunology ,Immunosuppression ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,medicine.disease ,Biochemistry ,Gastroenterology ,Transplantation ,Letermovir ,Internal medicine ,medicine ,business ,Viral load ,Hemorrhagic cystitis ,medicine.drug - Abstract
Introduction: The preferred method for haploidentical stem cell transplantation (haploSCT) is currently the use of post-transplantation cyclophosphamide (PTCY) since it obviates the need for depletion of T lymphocytes, which is associated with profound immunosuppression. Despite preservation of non-alloreactive donor T cells, reconstitution of pathogen-specific immunity may be delayed even after T cell replete haploSCT. The incidence and clinical sequelae of viral reactivation may thus compromise the outcomes of the procedure. Patients and Methods: The study included 47 patients, who underwent haploSCT with PTCY from 12/2013 until 05/2019 and achieved stable donor engraftment. Median age at transplant was 53 years (range, 19-70). The indications for transplant were acute myeloid (n=19) or lymphoblastic (n=10) leukemia, myelodysplastic syndrome (n=10), myelofibrosis (n=4), chronic myeloid (n=2) or lymphocytic (n=1) leukemia, and T-prolymphocytic leukemia (n=1). Myeloablative conditioning was mainly utilized (n=36), with the exception of certain patients who received reduced-intensity (n=10) or non-myeloablative (n=1) regimens. The graft source was peripheral blood in 29 and bone marrow in 18 cases. Tacrolimus in combination with mycophenolate mofetil was administered for prevention of graft-versus-host disease. Recipient/donor cytomegalovirus (CMV) serostatus was -/- (n=2), -/+ (n= 5), +/- (n=11), or +/+ (n=29). CMV, Epstein-Barr virus (EBV), and human herpesvirus-6 (HHV-6) reactivation was monitored by real-time quantitative PCR (RQ-PCR) in plasma and/or leukocytes weekly for at least 6 months post haploSCT. BK virus (BKV) reactivation was assessed by RQ-PCR in urine and/or blood specimens in cases with symptoms suggestive of hemorrhagic cystitis (HC). Prophylaxis with letermovir was available in 1 patient only, and preemptive antiviral therapy was the principal modality for the management of CMV infection. Cellular immunity reconstitution was assessed by flow cytometry at 3, 6, and 12 months after transplant. Results: With a median follow-up time of 30 months (range, 2-64), the cumulative incidences (CIN) of relapse and non-relapse mortality (NRM) were 13.4% (95% confidence interval [CI], 5.4-25.1%) and 31.4% (95% CI, 18.3-45.4%) at 2 years, respectively. Disease-free (DFS) and overall survival (OS) were 55.2% (95% CI, 42.3-72.1%) and 61.8% (95% CI, 48.9-78.1%) at 2 years, respectively. The CIN of CMV reactivation (>100 copies/ml) plateaued at 75.6% (95% CI, 60.1-85.7%) at 3 months. CMV infection developed in 34 out of 45 patients who were at risk, whereas recurrent CMV reactivation was observed in 17 patients with a median number of 1.5 episodes (range, 1-6) per patient. The median total duration of antiviral therapy for CMV infection was 27 days (range, 14-199). CMV disease (pneumonia) was documented in 2 patients. The CIN of EBV reactivation (>1,000 copies/ml) was 47.1% (95% CI, 34.2-63.9%) at 12 months. No case of EBV-related post-transplant lymphoproliferative disorder was observed, however preemptive therapy with rituximab was required in 2 patients with rapidly increasing EBV viral load. HHV-6 reactivation (>1,000 copies/ml) was observed in 6 patients (CIN, 10.6% at 6 months; 95% CI, 3.8-21.4%), but only one required therapy with foscarnet due to high viral load (>10,000 copies/ml). The CIN of BKV-related HC reached 27.7% (95% CI, 15.7-40.9%) at 3 months. Cystoscopy for bladder hemostasis was required in 5/13 and nephrostomy in 1/11 patients with HC. Reconstitution of helper T cell immunity was considerably delayed, with median absolute CD4+ cell counts of 83/uL (range, 7-337), 216/uL (range, 80-509), and 236/uL (range, 97-586) at 3, 6 and 12 months, respectively. Recurrent CMV infection was significantly associated with the recovery of CD4+ cells at 3 months (Figure; median CD4+ count of 191/uL versus 62/uL in patients with 1 and 2 or more episodes of CMV reactivation, respectively; p=0.009). Conclusions: HaploSCT with PTCY is associated with substantial rates of viral reactivation (especially CMV and BKV) resulting in the need for prolonged antiviral therapy and considerable morbidity. Strategies to prevent viral infection are strongly warranted in haploidentical stem cell transplantation. The timing and duration of such interventions (like letermovir or adoptive immunotherapy) may be guided by the tempo of immune reconstitution following haploSCT. Figure Disclosures Tsonis: Gilead: Other: Travel Grant; Astellas: Other: Travel Grants; Gilead: Other: Travel Grant; Aenorasis: Other: Travel Grant; Takeda: Other: Travel Grant; Pfizer: Other: Travel Grant; Innovis: Other: Travel Grant.
- Published
- 2019
8. PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) ± RADIOTHERAPY (RT)
- Author
-
Ioannis Kotsianidis, Paraskevi Roussou, Dimitrios Boutsis, Gerasimos Pangalis, Eirini Katodritou, Pavlina Konstantinidou, M.A. Dimopoulos, Konstantinos Anargyrou, Anna Pigaditou, Maria Kotsopoulou, E. Hadjiharissi, Evridiki Michali, Ekaterini Stefanoudaki, Argyris Symeonidis, Sotirios G. Papageorgiou, Vassiliki Pappa, P. Panayitidis, George Karianakis, Themistoklis Karmiris, Eleni Variami, Chryssa Vadikolia, Christos Poziopoulos, Theoni Leonidopoulou, Maria Tsirogianni, G. Kourti, Michail Michail, Sotirios Sachanas, Konstantinos Konstantopoulos, Maria Papaioannou, Effimia Vrakidou, T.P. Vassilakopoulos, Gabriella Gainaru, Maria K. Angelopoulou, Christina Kalpadakis, and E. Terpos
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Hematology ,General Medicine ,CHOP ,Radiation therapy ,Internal medicine ,medicine ,Primary Mediastinal Large B-Cell Lymphoma ,Rituximab ,business ,medicine.drug - Published
- 2019
9. PF297 COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)
- Author
-
T. Giannikos, Konstantinos Konstantopoulos, E. Constaninou, A. Liaskas, K. Sakellariou, Z. Mellios, I. Assimakopoulos, M. Bellia, D. Grentzelias, George Karianakis, T.P. Vassilakopoulos, Gabriella Gainaru, Themistoklis Karmiris, E. Katrodritou, Eleni Plata, Theoni Leonidopoulou, Sotirios G. Papageorgiou, Theodora Assimakopoulou, Eleni Papadaki, V. Xanthopoulos, Maria Tsirogianni, Stamatios Karakatsanis, P. Katsaouni, H. Giatra, Chrysovalantou Chatzidimitriou, Maria K. Angelopoulou, Christina Kalpadakis, Argyris Symeonidis, Vassiliki Pappa, Evgenia Verigou, Maria Arapaki, G. Kourti, and M. Bakiri
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,R-CHOP chemotherapy ,medicine ,Rituximab ,Primary Mediastinal Large B-Cell Lymphoma ,Hematology ,EPOCH (chemotherapy) ,CHOP ,business ,medicine.drug - Published
- 2019
10. Unusual discrepancy between CT and PET/CT in the initial staging of Hodgkin's lymphoma
- Author
-
Fotios V. Michelis, Demitrios N. Exarhos, Emmanouil Nikiforakis, Themistoklis Karmiris, and Ifigenia A. Tzannou
- Subjects
medicine.medical_specialty ,PET-CT ,Text mining ,Oncology ,business.industry ,Medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,General Medicine ,Radiology ,business ,Hodgkin's lymphoma ,medicine.disease - Published
- 2010
11. Intestinal pseudo-obstruction associated with amyloidosis
- Author
-
Sosanna Delimpasi, Konstantinos Liapis, Themistoklis Karmiris, and Fotios V. Michelis
- Subjects
Intestinal pseudo-obstruction ,Male ,Gastrointestinal tract ,Pathology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Amyloidosis ,Intestinal Pseudo-Obstruction ,Lumen (anatomy) ,Middle Aged ,urologic and male genital diseases ,medicine.disease ,Pathophysiology ,Laparotomy ,Occlusion ,Intestine, Small ,Internal Medicine ,medicine ,Humans ,business ,Infiltration (medical) - Abstract
Intestinal pseudo-obstruction is a condition characterised by clinical manifestations of mechanical obstruction of the intestine in the absence of any organic occlusion of the lumen. This syndrome has rarely been reported to complicate the course of systemic amyloidosis. We describe the case of a 64-year-old man who presented with the syndrome of small bowel pseudo-obstruction secondary to AL amyloid infiltration of the gastrointestinal tract. We comment on the pathophysiology and on the clinical importance of amyloidosis-associated intestinal pseudo-obstruction.
- Published
- 2011
12. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma
- Author
-
Panayiotis Panayiotidis, Themistoklis Karmiris, Konstantinos Konstantopoulos, Eleni Variamis, Theodoros P. Vassilakopoulos, Paraskevi Roussou, Nora-Athina Viniou, Evangelia M. Dimitriadou, Christos Kittas, Maria K. Angelopoulou, Panayiotis Repoussis, Penelope Korkolopoulou, Styliani I. Kokoris, Maria N. Dimopoulou, Nikos Constantinou, Gerassimos A. Pangalis, Ipatia Doussis-Anagnostopoulou, Efstratios Patsouris, Marie-Christine Kyrtsonis, Vassiliki A. Boussiotis, Athina Androulaki, and Marina P. Siakantaris
- Subjects
Risk ,medicine.medical_specialty ,Anemia ,Immunology ,Clinical prediction rule ,Biochemistry ,Gastroenterology ,Sensitivity and Specificity ,Severity of Illness Index ,Predictive Value of Tests ,Internal medicine ,Biopsy ,medicine ,Humans ,Stage (cooking) ,Neoplasm Staging ,Leukopenia ,medicine.diagnostic_test ,business.industry ,Incidence ,Cell Biology ,Hematology ,medicine.disease ,Prognosis ,Hodgkin Disease ,Surgery ,Lymphoma ,medicine.anatomical_structure ,B symptoms ,Bone marrow ,medicine.symptom ,business ,Bone Marrow Neoplasms - Abstract
We developed a clinical prediction rule for bone marrow involvement (BMI) in Hodgkin lymphoma based on 826 patients and validated it in 654 additional patients. Independent prognostic factors for BMI were x 1 , B symptoms; x 2 , stage III/IV prior to bone marrow biopsy; x 3 , anemia; x 4 , leukocytes fewer than 6 × 10 9 /L; x 5 , age 35 years or older; and x 6 , iliac/inguinal involvement. Each factor was graded as x i = 1, if present, or x i = 0, if absent. A simplified score Z s = 8x 1 + 6x 2 + 5x 3 + 5x 4 + 3x 5 + 3x 6 – 8 was assigned to each patient. The sensitivity, specificity, and positive and negative predictive value of this prediction rule was 97.8%, 51.5%, 10.6%, and 99.8%, respectively. In the validation group, they were 98.1%, 40.3%, 12.7%, and 99.6%. According to Z s value, 3 risk groups for BMI were defined: low risk (Z s s , 0-9; 37% of patients; 4.2% risk), and high risk (Z s ≥ 10, 20% of patients, 25.5% risk). Patients with low risk (stage IA/IIA without anemia and leukopenia; stage IA/IIA, younger than 35 years, with either anemia or leukopenia but no inguinal/iliac involvement; and stage IIIA/IVA without any of these 4 risk factors) do not need bone marrow (BM) biopsy. Patients with standard risk should be staged with unilateral biopsy, but patients with high risk may benefit from bilateral biopsy.
- Published
- 2004
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.